EGFR and neoplasm: EVs, which were decorated with ligands specific for EGFR, conjugated to phospholipid (DMPE)-PEG were reported to target EGFR-overexpressing tumor cells with increased cell specificity and prolonged circulation time (Kooijmans et al., 2016).